- Conditions
- Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
- Interventions
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
- Drug
- Lead sponsor
- Innoviva Specialty Therapeutics
- Industry
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 2,481
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Facioscapulohumeral Muscular Dystrophy
- Interventions
- ACE-083, ACE-083 or placebo
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more
- Conditions
- Influenza
- Interventions
- DNA vaccine, TIV
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
- Conditions
- Cancer
- Interventions
- TTX-080, pembrolizumab, cetuximab, FOLFIRI
- Drug
- Lead sponsor
- Tizona Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more
- Conditions
- Metastatic Melanoma
- Interventions
- NEO-PV-01, Nivolumab, Adjuvant, APX005M, ipilimumab
- Biological · Other
- Lead sponsor
- BioNTech US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 4 more
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma
- Interventions
- BGB-53038, Tislelizumab, Cetuximab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more
- Conditions
- Breast Neoplasms
- Interventions
- PF-06804103, PF-06804103 + Palbociclib +Letrozole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Monica, California + 14 more
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
- Combination Product
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
- Interventions
- VIP152, BTKi
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA)
- Interventions
- OPGx-RDH12
- Drug
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Idiopathic Parkinson´s Disease, Parkinson's Disease
- Interventions
- RNDP-001, Syringe Front-Loading Device
- Biological · Device
- Lead sponsor
- Kenai Therapeutics
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Los Angeles, California • Columbus, Ohio
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
- Interventions
- DRP-104, atezolizumab
- Drug · Biological
- Lead sponsor
- Dracen Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more
- Conditions
- Metastatic Melanoma, Advanced Melanoma
- Interventions
- XmAb22841, XmAb23104
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
- Interventions
- AVA6000
- Drug
- Lead sponsor
- Avacta Life Sciences Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas • Seattle, Washington
- Conditions
- Clear Cell Renal Carcinoma
- Interventions
- MK-3475, Bevacizumab
- Drug
- Lead sponsor
- Arkadiusz Z. Dudek, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 5 more
- Conditions
- Neoplasms
- Interventions
- ZSTK474
- Drug
- Lead sponsor
- Zenyaku Kogyo Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Philadelphia, Pennsylvania
- Conditions
- Lung Neoplasm Malignant
- Interventions
- MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan, Cetuximab, Rescue Medications
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Clermont, Florida • Chicago, Illinois • Portland, Oregon
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
- Interventions
- Sonrotoclax, Zanubrutinib
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Fort Wayne, Indiana • Westwood, Kansas + 3 more
- Conditions
- Non-small Cell Lung Cancer Adenocarcinoma
- Interventions
- grapiprant and pembrolizumab
- Drug
- Lead sponsor
- Arrys Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Stanford, California • Detroit, Michigan • Grand Rapids, Michigan + 2 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Lunresertib, RP-3500, Debio0123
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • New Haven, Connecticut + 12 more
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986416, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Hackensack, New Jersey + 3 more
- Conditions
- Neoplasms
- Interventions
- Refametinib (BAY86-9766), Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Detroit, Michigan • St Louis, Missouri + 2 more
- Conditions
- Metastatic Renal Cell Carcinoma, Brain Metastases
- Interventions
- Cabozantinib, Nivolumab, Stereotactic Radiosurgery (SRS)
- Drug · Device · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Norovirus
- Interventions
- CDI-988, Placebo, Snow Mountain Virus
- Drug · Other
- Lead sponsor
- Cocrystal Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Decatur, Georgia